MJMaria Jacob

Maria Jacob

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria Jacob has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predicting lung nodules malignancy

    by M. Jacob, J. Romano, D. Araújo, J.M. Pereira, I. Ramos, V. Hespanhol

    It is critical to developing an accurate method for differentiating between malignant and benign solitary pulmonary nodules. This study aimed was to establish a predicting model of lung nodules malignancy in a real-world setting. The authors retrospectively analysed the clinical and computed tomography (CT) data of 121 patients with lung nodules, submitted to percutaneous CT-guided transthoracic biopsy, between 2014 and 2015. Multiple logistic regression was used to screen independent predictors for malignancy and to establish a clinical prediction model to evaluate the probability of malignancy. From a total of 121 patients, 75 (62%) were men and with a mean age of 64.7 years old. Multivariate logistic regression analysis identified six independent predictors of malignancy: age, gender, smoking status, current extra-pulmonary cancer, air bronchogram and nodule size (p<0.05). The area under the curve (AUC) was 0.8573. The prediction model established in this study can be used to assess the probability of malignancy in the Portuguese population, thereby providing help for the diagnosis of lung nodules and the selection of follow-up interventions.


  • Open Access

    Non-invasive ventilation in the elderly – never too late!

    by Leonor Mendonça Almeida, Maria Jacob, Mafalda Van Zeller, Tiago Pinto, Miguel Gonçalves, Marta Drummond

    Dear Editor, Practising evidence-based medicine in an ageing population is challenging. Nevertheless, using age as a diagnostic or therapeutic procedure contraindication is less and less common. Domiciliary non-invasive ventilation (NIV) in chronic respiratory failure patients has been largely used; however, data from older people is scarce...

  • Open Access

    Cystic fibrosis and amyotrophic lateral sclerosis, an unexpected association

    by M. Jacob, C.G. Cardoso, M. Redondo, M. Gonçalves, M. Pinto, A. Amorim

  • Open Access

    The effect of alcohol consumption in the treatment of nontuberculous mycobacteria

    by Maria Jacob, Ricardo Silva, Rita Gaio, Raquel Duarte


  • Open Access

    Diagnostic yield and safety of transbronchial cryobiopsy in sarcoidosis

    by Maria Jacob, Hélder Novais Bastos, Patrícia Caetano Mota, Natália Melo, Rui Cunha, José Miguel Pereira, Susana Guimarães, Conceição Souto Moura, António Morais

    Introduction: Transbronchial lung cryobiopsy (TBLC) is an endoscopic technique proven to be useful in diagnostic approach to interstitial lung disease (ILD), but its role in sarcoidosis is not fully established. The aim of the present study was to assess the diagnostic yield of TBLC in sarcoidosis and its safety profile.Methods: Retrospective analysis of patients, evaluated in a tertiary hospital ILD outpatient clinic, who underwent TBLC in the diagnostic work-up. TBLC was performed in accordance with the 2018 expert statement from the Cryobiopsy Working Group.Results: 32 patients were included (mean±sdage 47.7±12.6 years, 59.4% male) and divided into three groups: highly likely sarcoidosis (n=21), possible sarcoidosis (n=6) and unlikely sarcoidosis (n=5). A mean of 2.8±0.8 TBLCs were performed. The definitive diagnosis was established by TBLC in 20 out of 27 patients with suspected sarcoidosis. Two patients were diagnosed with sarcoidosis by other methods performed afterwards. TBLC leaded to other diagnosis as well, such as fungal infection (n=1), hypersensitivity pneumonitis (n=1) and silicosis (n=3), making the diagnostic yield for suspected sarcoidosis of TBLC of 92.6%. TBLC was also able to show compatible histological features in five patients whom sarcoidosis was not previously considered. The complications reported overall were pneumothorax in five (15.6%) patients and moderate bleeding in one (3.1%) case.Conclusion: In this cohort, TBLC was a safe, reliable and useful procedure in sarcoidosis diagnosis. These results suggest that TBLC can be used successfully in those cases where a definitive diagnosis could not be reached with the usual and less-invasive diagnostic tools.


  • Predicting factors for sarcoidosis outcome: retrospective cohort study

    by Maria Jacob, Hélder Novais Bastos, Patrícia Caetano Mota, Natália Melo, Rui Cunha, José Miguel Pereira, Susana Guimarães, Conceição Souto Moura, António Morais

    Background: Sarcoidosis is a systemic granulomatous inflammatory disease of unknown etiology with heterogeneous outcomes that range from spontaneous resolution to disabling chronic disease. Aim: to investigate clinical prognostic markers that can predict the long term outcome. Methods: Retrospective analysis of 173 sarcoidosis patients (58.5% females, with a median age of 34 [IQR 29-41] years), who presented different outcomes after a minimum follow-up of 2 years: spontaneous remission, resolving with treatment and chronic disease with treatment. Results: Spontaneous remission was associated with younger age at diagnosis, erythema nodosum, arthralgias, hilar lymph node enlargement, preserved DLCO and higher lymphocyte CD4/CD8 ratio. Chronic disease was associated with the absence of constitutional symptoms, worse pulmonary function tests, higher number of organs involved and more frequent extrapulmonary disease, specially skin. Multinomial logistic regression analysis showed that age, DLCO, lymphocyte CD4/CD8 ratio and the number of organs involved were independent predictors to differentiate chronic disease cases from those who will experience spontaneous remission. On the other hand, it was not able to find significant factors associated with treatment response, since these patients usually had common features with either comparing groups. Conclusion: We identified several significant prognostic factors that enable physicians to stratify patients according to the expected outcome and help them to correctly identify which patients may benefit from treatment.

  • Negative predictive value of lung cancer staging by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration

    by Maria Jacob, Catarina Sousa, Vanessa Santos, Maria Sucena, Adriana Magalhães, Gabriela Fernandes

    Background: Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) is the first step for nodal staging in lung cancer. However, it remains unclear whether mediastinoscopy is always required after a negative EBUS-TBNA result. Aim: To determine the true negative value of EBUS-TBNA for lung cancer staging based on the pathologic staging. Methods: Retrospective analysis of patients submitted to EBUS-TBNA for preoperative lung cancer staging, between 2009 and 2016. Lymph nodes (LNs) with a cytologic diagnose of “reactive LN” were included for this study. A true-negative result was defined as N0/N1 and a false-negative as N2/N3 confirmed in the pathologic staging. Results: Among 758 patients sampled, 44 patients met the study criteria. The mean age was 65.1±8.5 years, and 40 patients (90.9%) were men. Thirty one (70.5%) were adenocarcinoma and 12 (27.3%) were squamous cell carcinoma. A total of 270 punctures of LNs stations were done (mean ultrasonographic size 10 ± 3.1 mm, range of 3.7-26.2 mm), with a median of six punctures per patient. The overall negative predictive value of EBUS-TBNA in this setting was 88.6%, with false negative results only found in 5 patients, three of them with nodal metastasis out of the reach of EBUS-TBNA (regions 3 and 8). No major complications occurred in this cohort of EBUS-TBNA. Conclusion: EBUS-TBNA has a high NPV for lung cancer staging, confirming that this endoscopic technique is safe and effective in the preoperative staging. In this setting, a low risk negative LNs might not need further confirmation by mediastinoscopy.

  • Diagnostic yield and safety of transbronchial cryobiopsy in sarcoidosis

    by Maria Jacob, Hélder Novais Bastos, Patrícia Caetano Mota, Natália Melo, Rui Cunha, José Miguel Pereira, Susana Guimarães, Conceição Souto Moura, António Morais

    Introduction: Transbronchial lung cryobiopsy (TBLC) is an endoscopic technique that has been proven to be useful in diffuse lung diseases (DLD) diagnostic approach, but its role in sarcoidosis is not fully established. Aim: To access the diagnostic yield of TBLC in the sarcoidosis and its safety profile. Methods: Retrospective analysis of patients, evaluated in a tertiary hospital DLD outpatient clinic, who underwent TBLC in the diagnostic work-up. TBLC was performed according with 2018 Expert statement from the Cryobiopsy Working Group. Results: A total of 32 patients, with a mean age of 47.7 (±12.6) years old and 59.4% males, were included according to 3 groups: typical clinical and radiological features of sarcoidosis (n=21), patients in which the differential diagnosis included sarcoidosis (n=6) and patients in which the initial differential diagnosis did not include sarcoidosis (n=5). A mean of 2.8 TBLCs (±0.8) were performed per patient. The definitive diagnosis of sarcoidosis was established by TBLC in 20 out of 27 patients with suspected sarcoidosis. Two patients were diagnosed with sarcoidosis by other methods performed afterwards. TBLC also was able to reach other diagnosis, that included fungal infection (n=1), hypersensitivity pneumonitis (n=1) and silicosis (n=3), making the diagnostic yield of TBLC of 92.6%. The complications reported overall were pneumothorax in 5 (15.6%) patients and moderate bleeding in 1 (3.1%) case. Conclusion: In this cohort, TBLC was a safe, reliable and useful procedure in the sarcoidosis diagnosis. These results suggest that TBLC can be used successfully in those cases where a definitive diagnosis could not be reached with the usual and less invasive diagnostic tools.

  • Open Access

    Targeted Gene Next-Generation Sequencing Panel in Patients with Advanced Lung Adenocarcinoma: Paving the Way for Clinical Implementation

    by Maria Gabriela O. Fernandes, Maria Jacob, Natália Martins, Conceição Souto Moura, Susana Guimarães, Joana Pereira Reis, Ana Justino, Maria João Pina, Luís Cirnes, Catarina Sousa, et al.

    Identification of targetable molecular changes is essential for selecting appropriate treatment in patients with advanced lung adenocarcinoma. Methods: In this study, a Sanger sequencing plus Fluorescence In Situ Hybridization (FISH) sequential approach was compared with a Next-Generation Sequencing (NGS)-based approach for the detection of actionable genomic mutations in an experimental cohort (EC) of 117 patients with advanced lung adenocarcinoma. Its applicability was assessed in small biopsies and cytology specimens previously tested for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutational status, comparing the molecular changes identified and the impact on clinical outcomes. Subsequently, an NGS-based approach was applied and tested in an implementation cohort (IC) in clinical practice. Using Sanger and FISH, patients were classified as EGFR-mutated (n = 22, 18.8%), ALK-mutated (n = 9, 7.7%), and unclassifiable (UC) (n = 86, 73.5%). Retesting the EC with NGS led to the identification of at least one gene variant in 56 (47.9%) patients, totaling 68 variants among all samples. Still, in the EC, combining NGS plus FISH for ALK, patients were classified as 23 (19.7%) EGFR; 20 (17.1%) KRAS; five (4.3%) B-Raf proto-oncogene (BRAF); one (0.9%) Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2); one (0.9%) STK11; one (0.9%) TP53, and nine (7.7%) ALK mutated. Only 57 (48.7%) remained genomically UC, reducing the UC rate by 24.8%. Fourteen (12.0%) patients presented synchronous alterations. Concordance between NGS and Sanger for EGFR status was very high (κ = 0.972; 99.1%). In the IC, a combined DNA and RNA NGS panel was used in 123 patients. Genomic variants were found in 79 (64.2%). In addition, eight (6.3%) EML4-ALK, four (3.1%), KIF5B-RET, four (3.1%) CD74-ROS1, one (0.8%) TPM3-NTRK translocations and three (2.4%) exon 14 skipping MET Proto-Oncogene (MET) mutations were detected, and 36% were treatable alterations. Conclusions: This study supports the use of NGS as the first-line test for genomic profiling of patients with advanced lung adenocarcinoma.